$35.70 0.06 (0.17%)
12:51 EDT PFE Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 208.83B
PE Ratio 9.92
Volume (Avg. Vol.) 5.63M
Day's Range 35.52 - 35.89
52-Week Range 27.88 - 40.97
Dividend & Yield 1.36 (3.81%)
PFE Stock Predictions, Articles, and Pfizer News
- From InvestorPlace
- From the Web
PFE's dividend yield as well as prospects for a Covid-19 vaccine should put Pfizer stock on the radar of long-term investors.
Expect Pfizer to skyrocket come October as it attempts to produce a vaccine for the novel coronavirus in record time. PFE stock is a buy.
By Ian Cooper
While airlines are still plenty of volatility, I’d use the weakness to pick up "blood in the street" opportunities like JBLU stock.
Pfizer stock kicked off the week with a big bang and coronavirus vaccine hopes. Here is how to profit from PFE right here.
Pfizer stock and partner BioNTech are rallying Monday morning on news the two companies could vaccinate Americans before the end of 2020.
Pfizer will have first-mover advantage with its Covid-19 vaccine. But that is not the only reason to be bullish on PFE stock.
Biotech stocks are on fire at the moment. That said, here are five names from the sector that offer long-term value and strong fundamentals.
As the pandemic continues to grow, these four coronavirus stocks are great ways to protect your portfolio for the foreseeable future.
Safe stocks have a low beta coupled with strong fundamentals, robust cash flows and an attractive dividend.
Let's dial up some earnings previews on Pfizer and McDonald's, and take a look at DraftKings and Hasbro as our top stock trades.
As the market continues to deal with the pandemic, these five cheap drug stocks have solid dividend yields of 4% and almost 37% upside.
AMD, Microsoft, Pfizer and Slack were our top stock trades from Wednesday. So, here's how the charts are looking now with earnings in play.
Market volatility is increasing. Here are seven robust companies whose shares are possibly among the best dividend-paying stocks for cautious investors
As pharmaceutical companies rush to manufacture coronavirus vaccine and drugs, it makes sense to hold some potential winners.
PFE stock is not that exciting, but it is on solid ground. Furthermore, the company is on the verge of a breakout on the Covid-19 front.
Shopify, Roku, RingCentral, Pfizer and FedEx were our top stock trades from Wednesday. So, let's look at the charts as we turn to Thursday.
Pfizer (PFE) news for Wednesday concerning one of its vaccines designed to treat the novel coronavirus has PFE stock taking off.
More than 30 biotech and pharmaceutical companies are racing to develop a safe Covid-19 vaccine. Several candidates entered late stage trials in a matter of months. Two of the companies developing a vaccine — Pfizer and Moderna — are utilizing a promising new technology using messenger RNA. Watch the video to learn why experts believe this vaccination method could be a game changer for getting back to normal.
From Seeking Alpha
Following through on President Trump's Executive Order in July aimed at cutting U.S. drug costs via importation, the FDA issues its final rule on allowing agency-authorized programs to import medicines, including biologics, from Canada under certain conditions that ensure safety.The guidance describes procedures drug makers can follow, including obtaining a National Drug Code (NDC), to facilitate the importation of prescription drugs and biologics that are FDA-approved, manufactured abroad, authorized for sale in any foreign country and originally intended for sale in that foreign country.The rule allows states (including the District of Columbia and territories), Indian tribes and — in certain future circumstances — pharmacists and wholesalers, to submit importation program proposals to the FDA for review and authorization.
Edison, NJ -- (SBWIRE) -- 09/24/2020 -- Global Smokeless Tobacco Treatment Market Insights by Application, Product Type, Competitive Landscape & Regional Forecast 2025 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Smokeless Tobacco Treatment Market. Some of the key players profiled in the study are Pfizer Inc. (United States), GlaxoSmithKline plc. (United Kingdom), Johnson & Johnson Services Inc. (United States), Novartis (Switzerland), Cigna (United States), Yesmoke (Italy), Habitrol (New Zealand), Perrigo Co. Plc. (Ireland) and Cambrex Corporation (United States).
Albany, NY -- (SBWIRE) -- 09/25/2020 -- Personalized medicine is tailoring of a treatment to a specific patient i.e. designing medicine treatment on the basis of diagnosis, disease condition, patient history, body physics, and other factors related to patients and diseases. Personalized medicine is also known as precision medicine, stratified medicine, or P4 medicine. In personalized medicine, diagnostic analysis is often conducted for selecting suitable and best treatments based on the patient's genetic content or other molecular or cellular analysis. Personalized medicine has best response and highest safety margin to ensure enhanced patient care by allowing every patient to attain earlier diagnosis, risk assessment, and best treatment. Additionally, personalized medicine offers opportunities to improve health care by lowering overall treatment costs.
Navellier RatingsPowered by Portfolio Grader